AngioDynamics Stock Sees Mixed Results, Down 10% Despite Q4 Sales and Earnings Beat

AngioDynamics reported Q4 2025 sales of $80.2 million and an adjusted loss of $0.03 per share, beating expectations. However, its GAAP loss was much higher at $0.15 per share. The company expects to lose money in fiscal 2026 and has a guidance range of $0.25 to $0.35 per share loss, adjusted for one-time items. The stock dropped 10% despite beating expectations, making it a sell according to some investors.

AngioDynamics Inc. (NASDAQ:ANGO) reported its fourth quarter and full-year fiscal 2025 results, revealing a mixed performance. The medical device company reported Q4 FY2025 revenue of $80.2 million, up 12.7% year-over-year on a pro forma basis. This growth was primarily driven by the Med Tech segment, which contributed $35.8 million, a 19.7% increase. However, the company reported an adjusted loss of $0.03 per share, but a GAAP loss of $0.15 per share, which was higher than expected [1].

AngioDynamics' CEO, Jim Clemmer, stated, "We delivered continued commercial and operational execution, driving profitable growth across our business." The company's cash position strengthened to $55.9 million, up from $44.8 million at the end of February 2025. Additionally, AngioDynamics secured a revolving line of credit providing access to up to $25 million [1].

The Med Tech segment, which includes Auryon, Thrombus Management, and NanoKnife product lines, continued to be the growth engine. Auryon, the atherectomy system, achieved Q4 sales of $15.6 million, representing 19.7% year-over-year growth. Thrombus Management delivered the strongest growth within the Med Tech segment, with Q4 sales of $13.0 million, a 45.6% increase. NanoKnife sales totaled $7.2 million, with disposables sales increasing by 5.5% [1].

For fiscal year 2026, AngioDynamics expects net sales of $305 million to $310 million, with Med Tech growth of 12-15% year-over-year and flat Med Device sales. The company expects gross margins between 53.5% and 55.5%, with pro forma adjusted EBITDA of $3.0 million to $8.0 million [1].

Despite beating expectations, AngioDynamics' stock dropped 10% in premarket trading, reaching $10.48. The stock has traded in a 52-week range of $5.83 to $13.50. Analysts at Lake Street Capital initiated coverage on shares of AngioDynamics, setting a "buy" rating and a $24.00 price target [2].

References:

[1] https://www.investing.com/news/company-news/angiodynamics-q4-2025-slides-med-tech-growth-drives-127-revenue-increase-93CH-4135927
[2] https://www.marketscreener.com/quote/stock/ANGIODYNAMICS-INC-8379/news/AngioDynamics-Inc-Provides-Earnings-Guidance-for-the-Fiscal-Year-2026-50511785/